Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## Why UHC Denies Checkpoint Inhibitors for "Medical Necessity"

A UnitedHealthcare medical-necessity denial for Keytruda, Opdivo, Yervoy, Tecentriq, Imfinzi, or Libtayo almost never means the drug doesn't work — it means the submitted clinical packet failed to map cleanly onto the Oncology Medication Clinical Coverage policy (eff. 04/01/2026) and its NCCN Compendium overlay. The denial mechanic is rule-bound, not discretionary, and that is exactly what makes it appealable.

The four failure modes UHC's reviewers actually cite:

1. NCCN Category 3 (or off-Compendium) use. UHC recognizes NCCN Categories 1, 2A, and 2B as proven; Category 3 is auto-denied as "unproven." If your indication is Category 2A but the prior auth was submitted without the exact NCCN regimen citation (algorithm page, version, recommendation tier), Optum reviewers default to "insufficient documentation." 2. Biomarker threshold not documented. First-line NSCLC monotherapy requires PD-L1 TPS ≥50% by an FDA-approved assay (22C3 pharmDx). MSI-H/dMMR or TMB-high indications require the corresponding pathology report attached. A missing or unsigned biomarker report is the single most common denial driver. 3. Preferred-product step missed. Under the 2026 policy, preferred/non-preferred status varies by indication. Libtayo is preferred in CSCC; Keytruda/Opdivo are non-preferred for CSCC and require intolerance/contraindication attestation per the Preferred Product Criteria. 4. Site-of-care or specialty pharmacy routing. Keytruda is medical-benefit but must dispense through OptumRx specialty (Tier 5). Buy-and-bill submissions outside the OptumRx channel trigger admin denials masquerading as medical necessity.

Insurer-specific lever. UHC routes oncology PA through Optum Rx Health Solutions and, for many commercial plans, the Optum Cancer Guidance Program. Your peer-to-peer must be scheduled with an Optum oncology medical director — not a generalist — and you must reference the exact policy version ("Oncology Medication Clinical Coverage, eff. 04/01/2026") and NCCN Compendium algorithm by version number. For ERISA plans, invoke 29 CFR §2560.503-1(h)(3)(iii) to demand the identity and credentials of the reviewing physician and the specific clinical rationale; vague "does not meet criteria" letters are facially deficient.

Federal hooks. Pinto v. Aetna Life Ins. Co., 10th Cir. 2014, controls the experimental/unproven burden — the plan must show the treatment is not generally accepted, and an NCCN 2A or 2B listing alone defeats that burden as a matter of law in most circuits. For Medicare Advantage members, 42 CFR §422.566 entitles you to a 72-hour expedited reconsideration when delay jeopardizes life or function; oncology timelines almost always qualify. 45 CFR §156.122 further requires ACA marketplace plans to cover drugs on the USP MBC class list, which captures most checkpoint inhibitors.

Tactical tip. Build the appeal as a one-page NCCN crosswalk: left column = UHC's denial sentence, right column = NCCN algorithm page + Category rating + biomarker result + FDA label citation. Attach the pathology report with PD-L1/MSI/TMB highlighted, the NCCN page as a PDF exhibit, and a signed physician attestation on the preferred-product step if non-preferred. File the external IRO request the same day you file the internal level-2 — under most UHC commercial certificates you can run them in parallel, and IROs overturn checkpoint-inhibitor denials at well above the 40% national average when the NCCN crosswalk is clean.